In a filing, Biomarin Pharmaceutical Inc revealed its GVP, Chief Accounting Officer Burkhart Erin unloaded Company’s shares for reported $91903.0 on Feb 24 ’25. In the deal valued at $68.38 per share,1,344 shares were sold. As a result of this transaction, Burkhart Erin now holds 13,105 shares worth roughly $0.93 million.
Then, Burkhart Erin bought 1,344 shares, generating $91,903 in total proceeds.
Before that, Guyer Charles Greg sold 5,278 shares. Biomarin Pharmaceutical Inc shares valued at $350,324 were divested by the EVP, Chief Technical Officer at a price of $66.37 per share. As a result of the transaction, Guyer Charles Greg now holds 68,909 shares, worth roughly $4.9 million.
Oppenheimer upgraded its Biomarin Pharmaceutical Inc [BMRN] rating to an Outperform from a a Perform in a research note published recently. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in mid November with a ‘”an Outperform”‘ rating. William Blair also remained covering BMRN and has decreased its forecast on October 30, 2024 with a “Mkt perform” recommendation from previously “an Outperform” rating.
Price Performance Review of BMRN
On Tuesday, Biomarin Pharmaceutical Inc [NASDAQ:BMRN] saw its stock jump 3.14% to $71.17. Over the last five days, the stock has gained 9.73%. Biomarin Pharmaceutical Inc shares have risen nearly 8.28% since the year began. Nevertheless, the stocks have fallen -20.90% over the past one year. While a 52-week high of $94.85 was reached on 02/25/25, a 52-week low of $60.63 was recorded on 01/16/25. SMA at 50 days reached $65.11, while 200 days put it at $74.32.
Levels Of Support And Resistance For BMRN Stock
The 24-hour chart illustrates a support level at 69.78, which if violated will result in even more drops to 68.39. On the upside, there is a resistance level at 72.07. A further resistance level may holdings at 72.97. The Relative Strength Index (RSI) on the 14-day chart is 72.81, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 3.60, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 4.51%. Stochastics %K at 84.22% indicates the stock is a selling.
